EP1443901A4 - Soluble drug extended release system - Google Patents

Soluble drug extended release system

Info

Publication number
EP1443901A4
EP1443901A4 EP02782303A EP02782303A EP1443901A4 EP 1443901 A4 EP1443901 A4 EP 1443901A4 EP 02782303 A EP02782303 A EP 02782303A EP 02782303 A EP02782303 A EP 02782303A EP 1443901 A4 EP1443901 A4 EP 1443901A4
Authority
EP
European Patent Office
Prior art keywords
extended release
release system
soluble drug
drug extended
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02782303A
Other languages
German (de)
French (fr)
Other versions
EP1443901A2 (en
Inventor
Victoria Rogers
Philippe J M Dor
Joseph A Fix
Hiroyuki Kojima
Kazuhiro Sako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Yamanouchi Pharma Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd, Yamanouchi Pharma Technologies Inc filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of EP1443901A2 publication Critical patent/EP1443901A2/en
Publication of EP1443901A4 publication Critical patent/EP1443901A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02782303A 2001-11-13 2002-11-12 Soluble drug extended release system Ceased EP1443901A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7877 1987-01-28
US787701A 2001-11-13 2001-11-13
PCT/US2002/036681 WO2003041656A2 (en) 2001-11-13 2002-11-12 Soluble drug extended release system

Publications (2)

Publication Number Publication Date
EP1443901A2 EP1443901A2 (en) 2004-08-11
EP1443901A4 true EP1443901A4 (en) 2010-06-16

Family

ID=21728577

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02782303A Ceased EP1443901A4 (en) 2001-11-13 2002-11-12 Soluble drug extended release system

Country Status (10)

Country Link
EP (1) EP1443901A4 (en)
JP (2) JP4882200B2 (en)
KR (2) KR101016619B1 (en)
CN (1) CN100534531C (en)
AU (1) AU2002348279C1 (en)
CA (1) CA2466657C (en)
MX (1) MXPA04004544A (en)
PL (1) PL374280A1 (en)
RU (1) RU2322263C2 (en)
WO (1) WO2003041656A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
JP4822092B2 (en) * 2003-09-01 2011-11-24 大正製薬株式会社 W / O / W type composite emulsion
US20060210625A1 (en) * 2003-11-04 2006-09-21 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
US8197846B2 (en) 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition
KR100638041B1 (en) * 2003-12-24 2006-10-23 주식회사 삼양사 A nanoparticle composition of a water-soluble drug for oral administration and a preparation method thereof
KR20110130441A (en) * 2009-03-25 2011-12-05 린텍 가부시키가이샤 Solid preparation
KR101319420B1 (en) * 2011-03-18 2013-10-17 한남대학교 산학협력단 Water-soluble positive-charged drug delivery system with sustained release behavior
WO2012140674A1 (en) * 2011-04-11 2012-10-18 Council Of Scientific & Industrial Research Surface induced disassembly of nano containers
CN102977413B (en) * 2011-09-07 2015-05-13 江南大学 New method for preparing micelles by compounding polymers
CN103083222B (en) * 2011-10-28 2015-08-19 江南大学 One kettle way prepares three-component polymer micelle
JP6041823B2 (en) 2013-03-16 2016-12-14 ファイザー・インク Tofacitinib oral sustained release dosage form
WO2022038409A1 (en) * 2020-08-19 2022-02-24 주식회사 모든바이오 Nanoparticles comprising glycyrrhizin and water-soluble drug, pharmaceutical composition containing same, and preparation methods therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1263392A (en) * 1968-05-21 1972-02-09 American Home Prod Sustained release drug composition
WO1997006787A2 (en) * 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
WO2000015198A1 (en) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control
EP0661045B1 (en) * 1992-09-18 2002-07-03 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release hydrogel preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6410466A (en) * 1987-07-01 1989-01-13 Brother Ind Ltd Data recording and reproducing method for magnetic disk
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
IT1297461B1 (en) * 1997-10-29 1999-12-17 Ciocca Maurizio PREPARATION OF CONTROLLED RELEASE TABLETS BASED ON COMPLEXES BETWEEN CARRAGENANO AND SOLUBLE BASIC DRUGS
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (en) * 2001-06-21 2004-02-25 Astrazeneca Ab PHARMACEUTICAL FORMULATION

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1263392A (en) * 1968-05-21 1972-02-09 American Home Prod Sustained release drug composition
EP0661045B1 (en) * 1992-09-18 2002-07-03 Yamanouchi Pharmaceutical Co. Ltd. Sustained-release hydrogel preparation
WO1997006787A2 (en) * 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
WO2000015198A1 (en) * 1998-09-14 2000-03-23 Ranbaxy Laboratories Limited Orally administered controlled drug delivery system providing temporal and spatial control

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATTWOOD D ET AL: "AGGREGATION OF ANTI DEPRESSANT DRUGS IN AQUEOUS SOLUTION", JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON; GB, vol. 30, no. 3, 1 January 1978 (1978-01-01), pages 176 - 180, XP008122056, ISSN: 0022-3573 *
KRISTMUNDSDOTTIR T ET AL: "CHITOSAN MATRIX TABLETS: THE INFLUENCE OF EXCIPIENTS ON DRUG RELEASE", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US LNKD- DOI:10.3109/03639049509069249, vol. 21, no. 13, 1 January 1995 (1995-01-01), pages 1591 - 1598, XP009026687, ISSN: 0363-9045 *
MAGGI L ET AL: "Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 23, no. 4, 15 February 2002 (2002-02-15), pages 1113 - 1119, XP004348129, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(01)00223-X *
TOLIAT T ET AL: "Controlled release (CR) tablet formulation of diltiazem HCL using different polymers as retardant substances", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 14, no. 11 SUPPL., November 1997 (1997-11-01), & ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS; BOSTON, MASSACHUSETTS, USA; NOVEMBER 2-6, 1997, pages S598, XP008121997, ISSN: 0724-8741 *

Also Published As

Publication number Publication date
JP2005508995A (en) 2005-04-07
JP4894958B2 (en) 2012-03-14
KR101016619B1 (en) 2011-02-23
EP1443901A2 (en) 2004-08-11
RU2004117848A (en) 2005-05-27
JP4882200B2 (en) 2012-02-22
PL374280A1 (en) 2005-10-03
CN100534531C (en) 2009-09-02
CN1612726A (en) 2005-05-04
CA2466657A1 (en) 2003-05-22
AU2002348279C1 (en) 2008-09-04
AU2002348279B2 (en) 2008-01-24
CA2466657C (en) 2011-02-01
WO2003041656A2 (en) 2003-05-22
MXPA04004544A (en) 2005-03-31
RU2322263C2 (en) 2008-04-20
JP2011068700A (en) 2011-04-07
KR20100123779A (en) 2010-11-24
WO2003041656A3 (en) 2003-10-23
KR101132969B1 (en) 2012-04-09
KR20050044424A (en) 2005-05-12

Similar Documents

Publication Publication Date Title
GB2377236B (en) Packer releasing system
EP1383376A4 (en) Pharmaceutical formulations for sustained release
HK1062151A1 (en) Cutaneous administration system
HUP0401438A3 (en) Drug delivery system
MXPA03003235A (en) Delayed release pharmaceutical formulations.
AU2002327068A1 (en) Immediate release tablet
AU2001283359A1 (en) Drug release (delivery system)
HK1077523A1 (en) Proliposomal drug delivery system
EP1411905A4 (en) Sustained release delivery system
HUP0104472A3 (en) Sustained release matrix systems for highly soluble drugs
EP1315094A4 (en) Agent system
EP1411904A4 (en) Sustained release pharmaceutical composition
HUP0301177A3 (en) Ion-strength independent sustained release pharmaceutical formulation
EP1443901A4 (en) Soluble drug extended release system
EP1453482A4 (en) Radioopaque sustained release pharmaceutical system
IL139177A0 (en) Sustained release drug delivery system
GB0103877D0 (en) Novel Drug Delivery system
GB0021487D0 (en) Pharmaceutical
GB0128138D0 (en) Pharmaceutical use
GB0325060D0 (en) Drug release system
GB9919664D0 (en) Slow release delivery system
AUPQ985200A0 (en) Slow release pharmaceutical preparation
AU149726S (en) Soluble capsule
AU151852S (en) Soluble capsule
GB0115136D0 (en) Drug delivery system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040512

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20100520

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTELLAS PHARMA INC.

Owner name: ASTELLAS PHARMA TECHNOLOGIES, INC.

17Q First examination report despatched

Effective date: 20101018

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASTELLAS PHARMA INC.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20121127